我國自主研發抗艾滋病新藥獲批上市大綱

China's first domesticAlly developed long-acting injectable AIDS drug will be available to the public in August, and is expected to benefit tens of thousands of people infected with HIV.

我國首款自主研發的長效注射用抗艾滋病新藥將於8月上市，有望造福於數十萬名艾滋感染者。

The drug, Albuvirtide, was recently approved by the State Drug Administration, according to a notice on the administration's website.

根據國家藥品監督管理局網站發佈的通知，新藥“艾博衛泰”近日獲批上市。

Developed by Nanjing-based Frontier Biotechnologies, the drug is said to be able to block the fusion of the virus and host cell membranes, interrupting the HIV life cycle in its earliest stage.

該藥由前沿生物藥業（南京）股份有限公司研發，據稱可以通過抑制病毒包膜與人體細胞膜的融合，從而在感染初始環節阻斷病毒複製週期。

It could potentially enhance patient compliance, improve quality of life and reduce treatment costs for HIV-infected patients, according to the company. Its price has not been released yet.

該公司表示，這款新藥有望提高患者的依從性，提高生活質量，降低艾滋病患者的治療成本。其價格目前還沒有公佈。

Zhao Jianzhong, an official with the administration's drug approval center, said in a news report that the drug "offers a new option for HIV treatment" in China.

國家藥品監督管理局藥品審批中心的官員趙建中在一則新聞報道中表示，這種藥物在中國“爲艾滋病治療提供了一種新的選擇”。

"We encourage clinical research and the domestic development of drugs, and at the same time, we are accelerating the introduction of imported drugs to meet the urgent needs of our HIV/AIDS patients," said Wang Tao, the head of the administration's drug approval center.

藥品審評中心負責人王濤稱：“我們鼓勵國內創新藥做臨牀研發，同時我們對國際上發達國家已經上市的藥物，也是儘快地把它引進到中國來，來解決我們的用藥需求。”